Relief Therapeutics Holding (XSWX:RLF) Cash per Share: CHF0.99 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RLF Relief Therapeutics Holding SA XSWX:RLF
20 GF Score
Price CHF3.00
GF Value CHF6.28
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Cash per Share?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 Cash per Share is CHF0.99 as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Relief Therapeutics Holding's Cash per Share for the quarter that ended in Jun. 2025 was CHF0.99.

Relief Therapeutics Holding  (XSWX:RLF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Relief Therapeutics Holding Cash per Share Related Terms

Relief Therapeutics Holding Cash per Share Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Cash per Share Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 4.35 1.75 1.16 1.20

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.16 0.86 1.20 0.99
XSWX:RLF
20GF Score
Relief Therapeutics Holding SA XSWX:RLF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Relief Therapeutics Holding's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=15.08/12.54
=1.20

Relief Therapeutics Holding's Cash per Share for the quarter that ended in Jun. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=12.5/12.58
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of CHF0.99 mean?
Relief Therapeutics Holding (XSWX:RLF) has a Cash per Share of CHF0.99 as of Jun. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Cash per Share too high?
Relief Therapeutics Holding's current Cash per Share is CHF0.99. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Cash per Share compare to KTTA and OSRH?
Relief Therapeutics Holding's Cash per Share of CHF0.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Cash per Share is CHF0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Cash per Share of CHF0.99. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Cash per Share is CHF0.99. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Cash per Share is CHF0.99 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

  • Cash per Share: CHF0.99
  • GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score

Get the complete analysis for XSWX:RLF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00
Price
CHF6.28
GF Value